Blood Thinners Before Microblading: The Bigger Risk Isn't Always the Bleeding
About the Author
Airton Barbalho, BS, is a Biomedical Aesthetics Specialist and founder of AB Clínica de Medicina Estética in Castellón de la Plana, Spain. He has 11+ years of clinical experience in advanced micropigmentation, and also works in laser dermatology. He is the creator of the Endermo Prime method for the treatment of white striae, and has trained more than 500 professionals across six countries. His clinical research has been published in Our Dermatology Online and featured in MedEsthetics. In 2025, he was invited as a speaker at the Global Integral Beauty Conference in New York, where he also received the Revelation Award. ORCID: 0009-0001-7321-5622. Website: airtonbarbalho.com
Barbalho Rodrigues A. Anticoagulant therapy in eyebrow microblading: low hemorrhagic risk, underreporting patterns, and the thromboembolic hazards of unsupervised drug withdrawals. Our Dermatology Online. 2026;17(4). DOI: 10.7241/ourd.20264.4
Barbalho Rodrigues A. Combined vacuum therapy and superficial micropuncture in the treatment of white striae: A case series. Our Dermatol Online. 2026;17(2):266-267. DOI: 10.7241/ourd.20262.26
___________________________________________________________
If you ask ten experienced microblading artists what they tell clients on blood thinners, you'll likely get ten different answers. Physician clearance for some. A quiet suggestion to skip the pills for a few days for others. Plenty just proceed and deal with whatever bleeding shows up. These approaches may seem pragmatic from a procedural perspective, but they are not medically equivalent, and advising a client to alter prescribed medication falls outside the PMU practitioner's scope.
Blood Thinners and Microblading: Why This Question Matters
Anticoagulant and antiplatelet therapy is far more common among microblading clients than most artists assume. Conditions like atrial fibrillation, a history of stroke or deep vein thrombosis, coronary artery disease, and mechanical heart valves are among the conditions for which long-term anticoagulant or antiplatelet therapy may be prescribed. As the client base for permanent makeup skews older and includes more people managing cardiovascular conditions, this question comes up constantly during intake.
"Blood thinners" is a convenient shorthand, but it covers pharmacologically distinct drugs. Warfarin blocks vitamin K-dependent clotting factors; direct oral anticoagulants like apixaban and rivaroxaban inhibit specific clotting factors directly; aspirin and clopidogrel act earlier, on platelet aggregation. Each carries its own bleeding profile and its own considerations around stopping it, especially in patients with mechanical heart valves, atrial fibrillation, recent venous thromboembolism, or coronary stents. Treating all of them as one category misses that.
What Actually Happens When a Client Stops Their Medication Without Medical Guidance?
Stopping an anticoagulant is not a neutral decision. It doesn't just remove a bleeding risk and leave everything else the same. For many patients, these medications exist specifically to prevent a clot, a stroke, or a second cardiac event. Interrupting therapy for even a few days can reintroduce a real thromboembolic risk, and that risk has nothing to do with the cosmetic procedure. It has everything to do with the condition the medication was prescribed for in the first place.
Telling a client to "just stop it for a few days" isn't a safer alternative. It's asking the client to alter a prescribed treatment in an attempt to reduce procedural bleeding while potentially reintroducing the thromboembolic risk the medication was prescribed to prevent, a clinical trade-off the PMU practitioner is not qualified to assess.
What Does a Closer Look at Real Cases Actually Show?
A retrospective review of intake records from my own practice, spanning 250 documented client anamneses, identified 11 cases involving anticoagulant or antiplatelet therapy. The subgroup wasn't further broken down by specific medication, indication, or dual-therapy status. In these cases, bleeding was manageable with standard technique adjustments and local hemostatic measures, and none required stopping the medication. To clarify what "manageable" means here: in the cases reviewed, bleeding generally presented as fine, pinpoint droplets associated with the individual strokes rather than continuous or free-flowing bleeding, and was controlled with standard local measures. The finding is consistent with the broader literature on anticoagulation and minor dermatologic procedures, which offers supportive though indirect evidence, since it isn't specific to microblading. Direct, high-quality data on anticoagulated patients undergoing this exact procedure remains limited.
That doesn't mean every case is risk-free, or that bleeding risk can be waved away. A series this size, from a single practice, isn't grounds to claim a uniformly low bleeding risk across every anticoagulated or antiplatelet patient. What it actually shows is more limited: in the cases reviewed, bleeding was something a practitioner could manage. The risk from unsupervised medication withdrawal is a different matter entirely, and it's not something a PMU artist is positioned to evaluate.
Where Does This Leave the Artist During Intake?
Right at the edge of your scope. Asking about anticoagulant and antiplatelet use during intake is not just fine, it's necessary. Instructing a client to modify her medication regimen is a different matter entirely, and it isn't the artist's call. That decision belongs to the prescribing physician, who can weigh the client's actual cardiovascular risk against the bleeding risk of the procedure itself, a balance that depends on the specific medication, indication, and clinical history, not something a blanket rule can settle.
A responsible intake process asks the question, documents the answer, adjusts technique and aftercare expectations accordingly, and loops in the physician when the client's history or medication profile calls for it, rather than as an automatic reflex for every client on blood thinners. Where exactly that line falls depends on the practitioner's local regulations and scope of practice, which differ enough from one country to the next that no blanket answer covers every case.
A Related Point Worth Flagging: Vasoconstrictors in Topical Anesthetics
This article is about anticoagulant and antiplatelet therapy specifically, but one adjacent point deserves a brief mention: some topical anesthetics used in PMU contain vasoconstrictive agents that act at the capillary level. That's not an endorsement or a warning against their use. Product selection should follow the product's own labeling and contraindications, within the practitioner's scope of practice, with medical consultation sought where a client's history raises a specific concern. Bleeding control in PMU isn't only about what a client is taking systemically; it can also depend on what's applied to the skin during the procedure itself.
The Bottom Line
None of this is meant to establish that microblading is safe for every client on anticoagulant or antiplatelet therapy; that's not a claim this article makes either way. The point is narrower: medication-management decisions sit outside a PMU practitioner's scope. Anticoagulant or antiplatelet therapy shouldn't be treated as an automatic reason to turn a client away, but it isn't something to manage by suggesting a pause in medication either. Each case still calls for individual judgment, within your local regulations and scope of practice. Ask better questions at intake. Document what you learn. Adjust your technique where it matters, and know exactly where your scope ends and a physician's begins.
Disclaimer: This article is an independent contribution by the author and reflects the author’s clinical experience, research, and interpretation of the available literature. The views expressed do not necessarily represent those of PULSE PMU. This content is provided for educational and informational purposes only and does not constitute medical advice or clinical guidance. Decisions regarding anticoagulant or antiplatelet therapy must be made by the client’s prescribing physician. PMU practitioners should never advise clients to start, stop, or modify prescribed medication.
#PermanentMakeup #Microblading #Micropigmentation #PMU #PMUEducation #PMUSafety #PMUProfessionals #Anticoagulants #AntiplateletTherapy #BloodThinners #ClientSafety #PatientSafety #ClientConsultation #MedicalMicropigmentation #AestheticMedicine #EvidenceBasedPractice #ClinicalSafety #ScopeOfPractice #AirtonBarbalho #PULSEPMU #PermanentMakeupEducation
Publication date: September 4, 2026
By Airton Barbalho, ORCID: 0009-0001-7321-5622
Comments